復星醫藥AH股齊漲 正積極推進輝瑞mRNA新冠核酸疫苗中國臨牀
格隆匯12月3日丨港A市場疫苗股集體上漲,其中,復星醫藥A股漲超4%,H股漲超5%。昨日輝瑞、BioNTech宣佈,聯合研發的mRNA新冠疫苗已經獲得了英國政府的臨時性緊急使用授權,該疫苗將從下週開始在全英國提供。復星醫藥持有輝瑞新冠疫苗在中國的相關權益。11月24日,復星醫藥與BioNTech宣佈在中國江蘇泰州啟動BNT162b2的II期臨牀試驗,並計劃招募960名健康受試者,年齡段在18至85歲,以評估該候選疫苗的安全性和免疫原性,用於支持該疫苗在國內的上市申請。目前,復星醫藥在中國積極推進疫苗臨牀研究,加速mRNA核酸疫苗在國內上市步伐。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.